Table 1 Baseline demographic and clinical characteristics of subjects who maintained the eradicated state by quadruple therapy (EBMT) or moxifloxacin-based triple therapy (MEA)
Variable category | Total | EBMT | MEA | p-value* |
|---|---|---|---|---|
(N = 175) | (N = 59) | (N = 116) | ||
Gender | (N = 175) | (n = 59) | (n = 116) | |
Male | (104, 59.4%) | (35, 59.3%) | (69, 59.5%) | 0.98 |
Female | (71, 40.6%) | (24, 40.7%) | (47, 40.5%) | |
Age (years) (mean ± SD) | (N = 175) | (n = 59) | (n = 116) | 0.67 |
(56.6 ± 9.4) | (56.1 ± 9.3) | (56.8 ± 9.5) | ||
Clinical diagnosis | (N = 175) | (n = 59) | (n = 116) | |
Early gastric cancer | (40, 22.9%) | (11, 18.6%) | (29, 25.0%) | 0.06 |
Dysplasia | (19, 10.9%) | (3, 5.1%) | (16, 13.8%) | |
Peptic ulcer disease | (34, 19.4%) | (17, 28.8%) | (17, 14.7%) | |
Chronic gastritis | (82, 46.9%) | (28, 47.5%) | (54, 46.6%) | |
Histological AG in either antrum or body | (N = 116) | (n = 37) | (n = 79) | |
Yes | (67, 57.8%) | (21, 56.8%) | (46, 68.7%) | 0.88 |
No | (49, 42.2%) | (16, 43.2%) | (33, 41.8%) | |
Histological IM in either antrum or body | (N = 144) | (n = 47) | (n = 97) | |
Yes | (84, 58.3%) | (23, 48.9%) | (61, 62.9%) | 0.11 |
No | (60, 41.7%) | (24, 51.1%) | (36, 37.1%) |